STAT3-IN-12|西域试剂

STAT3-IN-12,99.92%

产品编号：Bellancom-150538| 分子式：C₂₈H₃₀N₄O₂| 分子量：454.56

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-150538	￥1500.00	杭州北京（现货）
Bellancom-150538	￥2500.00	杭州北京（现货）
Bellancom-150538	￥5500.00	杭州北京（现货）
Bellancom-150538	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

STAT3-IN-12

产品介绍

STAT3-IN-12 是一种有效的 STAT3 信号抑制剂，可以抑制 IL-6 诱导的 JAK/STAT3 信号通路的激活。STAT3-IN-12 可抑制癌细胞生长、迁移，并诱导细胞凋亡 (apoptosis) 以及周期阻滞。STAT3-IN-12 可用于癌症相关研究，如肝细胞癌 (HCC) 和食管癌。

生物活性

STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma.

体外研究

STAT3-IN-12 (compound 24, 0-10 μM approximately, 72 h) inhibits cancer cell growth and migration in HepG2 and EC109 cells.
STAT3-IN-12 (0-20 μM, 16 h) binds to the STAT3 protein and inhibits IL-6-mediated STAT3 phosphorylation, also inhibts STAT3 nuclear localization and dimerization in EC109 and HepG2 cells.
STAT3-IN-12 (0-20 μM, 48 h) induces cell apoptosis as well as cycle arrest in HepG2 and EC109 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	HepG2 and EC109 cells
Concentration:	0, 1.25, 2.5, 5 and 10 μM.
Incubation Time:	72 h
Result:	Inhibited cancer cell growth with IC₅₀ values of 4.32 and 3.63 μM.

Cell Migration Assay

Cell Line:	HepG2 and EC109 cells
Concentration:	0-10 μM
Incubation Time:	24 h
Result:	Inhibited cancer cell migration.

Western Blot Analysis

Cell Line:	HepG2 and EC109 cells
Concentration:	0, 2.5, 5, 10 and 20 μM
Incubation Time:	16 h
Result:	Inhibited phosphorylation of STAT3 tyrosine 705 with high selectivity.

体内研究
(In Vivo)

STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HepG2 cell xenograft tumor model
Dosage:	20, 40 mg/kg, daily for 24 days
Administration:	Intraperitoneal injection
Result:	Inhibited tumor growth without affecting the body weight.

体内研究

STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HepG2 cell xenograft tumor model
Dosage:	20, 40 mg/kg, daily for 24 days
Administration:	Intraperitoneal injection
Result:	Inhibited tumor growth without affecting the body weight.

体内研究

STAT3-IN-12 (compound 24, intraperitoneal injection, 20, 40 mg/kg, daily for 24 days) displays obvious antitumor activity in a mouse HepG2 cell xenograft tumor model without no obvious toxicity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HepG2 cell xenograft tumor model
Dosage:	20, 40 mg/kg, daily for 24 days
Administration:	Intraperitoneal injection
Result:	Inhibited tumor growth without affecting the body weight.